Ihuman Price To Sales Ratio vs Free Cash Flow Per Share Analysis

IH Stock

USD 1.64 0.08 5.13%

Ihuman financial indicator trend analysis is infinitely more than just investigating Ihuman Inc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ihuman Inc is a good investment. Please check the relationship between Ihuman Price To Sales Ratio and its Free Cash Flow Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Price To Sales Ratio vs Free Cash Flow Per Share

Price To Sales Ratio vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ihuman Inc Price To Sales Ratio account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have pay attention.

The correlation between Ihuman's Price To Sales Ratio and Free Cash Flow Per Share is -0.75. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Ihuman Inc, assuming nothing else is changed. The correlation between historical values of Ihuman's Price To Sales Ratio and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Ihuman Inc are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Price To Sales Ratio i.e., Ihuman's Price To Sales Ratio and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

-0.75

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Ihuman Inc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ihuman sales, a figure that is much harder to manipulate than other Ihuman Inc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Ihuman's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ihuman Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

As of now, Ihuman's Enterprise Value Multiple is increasing as compared to previous years.

	2021	2022	2023	2024 (projected)
Gross Profit	660.6M	691.2M	721.3M	483.8M
Total Revenue	944.7M	985.5M	1.0B	702.3M

Gross Profit Total Revenue

Ihuman fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock
Total Assets		0.62	0.99	1.0	0.97	0.73	0.99	-0.98	-0.65	0.9	1.0	0.94	0.87	0.86	1.0	0.97	0.95	0.87	0.99	-0.81	0.99	0.98	0.99	1.0	1.0	0.96
Other Current Liab	0.62		0.56	0.64	0.69	0.25	0.55	-0.73	0.05	0.49	0.63	0.54	0.62	0.54	0.63	0.5	0.55	0.76	0.56	-0.61	0.59	0.54	0.56	0.64	0.62	0.62
Total Current Liabilities	0.99	0.56		0.98	0.95	0.79	1.0	-0.97	-0.71	0.92	0.98	0.96	0.89	0.89	0.98	0.97	0.94	0.89	0.98	-0.78	0.99	0.98	1.0	0.98	0.99	0.95
Total Stockholder Equity	1.0	0.64	0.98		0.96	0.69	0.98	-0.98	-0.62	0.88	1.0	0.92	0.86	0.85	1.0	0.96	0.95	0.86	0.99	-0.82	0.98	0.97	0.98	1.0	1.0	0.95
Net Tangible Assets	0.97	0.69	0.95	0.96		0.74	0.96	-0.98	-0.6	0.92	0.97	0.89	0.79	0.78	0.97	0.95	0.9	0.85	0.96	-0.79	0.96	0.96	0.96	0.96	0.97	0.92
Property Plant And Equipment Net	0.73	0.25	0.79	0.69	0.74		0.77	-0.69	-0.74	0.93	0.71	0.87	0.76	0.8	0.71	0.71	0.68	0.73	0.75	-0.34	0.74	0.78	0.79	0.69	0.71	0.69
Current Deferred Revenue	0.99	0.55	1.0	0.98	0.96	0.77		-0.97	-0.71	0.92	0.99	0.95	0.86	0.87	0.99	0.98	0.94	0.87	0.98	-0.8	0.99	0.98	1.0	0.98	0.99	0.95
Net Debt	-0.98	-0.73	-0.97	-0.98	-0.98	-0.69	-0.97		0.59	-0.88	-0.98	-0.9	-0.85	-0.82	-0.98	-0.95	-0.93	-0.9	-0.96	0.85	-0.96	-0.96	-0.97	-0.98	-0.98	-0.95
Retained Earnings	-0.65	0.05	-0.71	-0.62	-0.6	-0.74	-0.71	0.59		-0.67	-0.65	-0.64	-0.55	-0.6	-0.65	-0.73	-0.76	-0.41	-0.72	0.59	-0.64	-0.77	-0.71	-0.62	-0.65	-0.73
Accounts Payable	0.9	0.49	0.92	0.88	0.92	0.93	0.92	-0.88	-0.67		0.89	0.95	0.83	0.84	0.89	0.88	0.81	0.84	0.91	-0.54	0.91	0.91	0.93	0.88	0.9	0.82
Cash	1.0	0.63	0.98	1.0	0.97	0.71	0.99	-0.98	-0.65	0.89		0.92	0.87	0.85	1.0	0.96	0.96	0.86	0.99	-0.82	0.99	0.98	0.98	1.0	1.0	0.96
Non Current Assets Total	0.94	0.54	0.96	0.92	0.89	0.87	0.95	-0.9	-0.64	0.95	0.92		0.95	0.96	0.92	0.87	0.87	0.94	0.92	-0.61	0.95	0.91	0.96	0.92	0.93	0.88
Non Currrent Assets Other	0.87	0.62	0.89	0.86	0.79	0.76	0.86	-0.85	-0.55	0.83	0.87	0.95		0.99	0.87	0.74	0.87	0.94	0.85	-0.62	0.86	0.84	0.89	0.86	0.86	0.87
Other Assets	0.86	0.54	0.89	0.85	0.78	0.8	0.87	-0.82	-0.6	0.84	0.85	0.96	0.99		0.85	0.75	0.86	0.92	0.85	-0.58	0.86	0.84	0.89	0.85	0.85	0.86
Cash And Short Term Investments	1.0	0.63	0.98	1.0	0.97	0.71	0.99	-0.98	-0.65	0.89	1.0	0.92	0.87	0.85		0.96	0.96	0.86	0.99	-0.82	0.99	0.98	0.98	1.0	1.0	0.96
Net Receivables	0.97	0.5	0.97	0.96	0.95	0.71	0.98	-0.95	-0.73	0.88	0.96	0.87	0.74	0.75	0.96		0.92	0.77	0.97	-0.83	0.97	0.98	0.97	0.96	0.97	0.92
Common Stock Total Equity	0.95	0.55	0.94	0.95	0.9	0.68	0.94	-0.93	-0.76	0.81	0.96	0.87	0.87	0.86	0.96	0.92		0.79	0.97	-0.87	0.92	0.97	0.94	0.95	0.96	0.99
Common Stock Shares Outstanding	0.87	0.76	0.89	0.86	0.85	0.73	0.87	-0.9	-0.41	0.84	0.86	0.94	0.94	0.92	0.86	0.77	0.79		0.83	-0.63	0.88	0.82	0.89	0.86	0.86	0.83
Capital Surpluse	0.99	0.56	0.98	0.99	0.96	0.75	0.98	-0.96	-0.72	0.91	0.99	0.92	0.85	0.85	0.99	0.97	0.97	0.83		-0.81	0.98	0.99	0.98	0.99	0.99	0.97
Inventory	-0.81	-0.61	-0.78	-0.82	-0.79	-0.34	-0.8	0.85	0.59	-0.54	-0.82	-0.61	-0.62	-0.58	-0.82	-0.83	-0.87	-0.63	-0.81		-0.77	-0.83	-0.78	-0.82	-0.82	-0.89
Other Current Assets	0.99	0.59	0.99	0.98	0.96	0.74	0.99	-0.96	-0.64	0.91	0.99	0.95	0.86	0.86	0.99	0.97	0.92	0.88	0.98	-0.77		0.96	0.99	0.98	0.99	0.92
Other Stockholder Equity	0.98	0.54	0.98	0.97	0.96	0.78	0.98	-0.96	-0.77	0.91	0.98	0.91	0.84	0.84	0.98	0.98	0.97	0.82	0.99	-0.83	0.96		0.98	0.97	0.98	0.97
Total Liab	0.99	0.56	1.0	0.98	0.96	0.79	1.0	-0.97	-0.71	0.93	0.98	0.96	0.89	0.89	0.98	0.97	0.94	0.89	0.98	-0.78	0.99	0.98		0.98	0.99	0.95
Net Invested Capital	1.0	0.64	0.98	1.0	0.96	0.69	0.98	-0.98	-0.62	0.88	1.0	0.92	0.86	0.85	1.0	0.96	0.95	0.86	0.99	-0.82	0.98	0.97	0.98		1.0	0.95
Total Current Assets	1.0	0.62	0.99	1.0	0.97	0.71	0.99	-0.98	-0.65	0.9	1.0	0.93	0.86	0.85	1.0	0.97	0.96	0.86	0.99	-0.82	0.99	0.98	0.99	1.0		0.96
Capital Stock	0.96	0.62	0.95	0.95	0.92	0.69	0.95	-0.95	-0.73	0.82	0.96	0.88	0.87	0.86	0.96	0.92	0.99	0.83	0.97	-0.89	0.92	0.97	0.95	0.95	0.96

Click cells to compare fundamentals

Ihuman Account Relationship Matchups

Ihuman fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	168.3M	1.0B	1.1B	1.3B	1.5B	945.7M
Other Current Liab	880K	90.1M	104.7M	118.8M	438.0M	459.9M
Total Current Liabilities	182.8M	399.2M	482.9M	561.1M	490.8M	410.5M
Total Stockholder Equity	(14.4M)	642.7M	608.4M	769.5M	957.8M	531.7M
Property Plant And Equipment Net	2.5M	12.9M	50.5M	22.0M	9.8M	18.0M
Current Deferred Revenue	71.8M	268.6M	303.0M	379.1M	318.6M	251.0M
Net Debt	(104.9M)	(855.1M)	(821.1M)	(1.0B)	(1.2B)	(1.1B)
Retained Earnings	(348.5M)	(386.0M)	(423.0M)	(321.2M)	(140.5M)	(147.5M)
Accounts Payable	10.3M	21.6M	30.5M	24.2M	22.1M	22.3M
Cash	104.9M	861.7M	855.4M	1.0B	1.2B	750.2M
Non Current Assets Total	5.3M	25.5M	85.6M	79.6M	68.1M	48.6M
Non Currrent Assets Other	2.7M	784K	7.8M	6.4M	8.7M	4.9M
Other Assets	2.7M	784K	7.8M	6.4M	7.4M	4.0M
Cash And Short Term Investments	104.9M	861.7M	855.4M	1.0B	1.2B	750.2M
Net Receivables	21.0M	78.3M	59.0M	81.9M	62.6M	58.0M
Liabilities And Stockholders Equity	168.3M	1.0B	1.1B	1.3B	1.5B	945.7M
Non Current Liabilities Total	82.1M	5.1M	9.6M	2.9M	1.9M	1.8M
Capital Surpluse	213.1M	1.1B	1.1B	1.1B	1.2B	751.9M
Inventory	20.7M	16.9M	28.1M	19.1M	16.5M	17.4M
Other Current Assets	574K	64.6M	72.9M	102.8M	89.5M	60.9M
Other Stockholder Equity	333.9M	1.1B	1.1B	1.1B	1.1B	844.0M
Total Liab	182.8M	404.3M	492.5M	563.9M	492.7M	414.1M
Net Invested Capital	(14.4M)	642.7M	608.4M	769.5M	957.8M	531.7M
Total Current Assets	163.1M	1.0B	1.0B	1.3B	1.4B	897.1M
Accumulated Other Comprehensive Income	0.0	(21.9M)	(34.7M)	18.5M	26.1M	27.4M
Cash And Equivalents	104.9M	861.7M	855.4M	1.0B	1.2B	633.2M
Net Working Capital	(19.7M)	622.2M	532.3M	692.7M	891.7M	486.6M
Short Term Debt	99.8M	1.5M	24.7M	6.1M	1.9M	1.8M
Intangible Assets	103K	11.8M	27.3M	24.9M	23.2M	16.0M
Property Plant Equipment	2.5M	12.9M	50.5M	22.0M	25.3M	19.5M

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

How To Invest In Ihuman

Details

Is Ihuman Stock a good investment?

Details

What is Ihuman's Net Worth?

Details

Largest Hotels, Restaurants & Leisure Companies

View

Largest Education & Training Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ihuman. If investors know Ihuman will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ihuman listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.40)

Earnings Share

(0.16)

Revenue Per Share

18.263

Quarterly Revenue Growth

(0.11)

Return On Assets

0.0456

The market value of Ihuman Inc is measured differently than its book value, which is the value of Ihuman that is recorded on the company's balance sheet. Investors also form their own opinion of Ihuman's value that differs from its market value or its book value, called intrinsic value, which is Ihuman's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ihuman's market value can be influenced by many factors that don't directly affect Ihuman's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ihuman's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ihuman is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ihuman's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ihuman Price To Sales Ratio vs Free Cash Flow Per Share Analysis

Price To Sales Ratio vs Free Cash Flow Per Share

Price To Sales Ratio vs Free Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Per Share

Ihuman fundamental ratios Correlations

Ihuman Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ihuman fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Current Deferred Revenue	+ 1.0	Total Current Liabilities

Total Current Assets	- 0.98	Net Debt
Net Invested Capital	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Net Debt	- 0.98	Net Tangible Assets
Net Debt	- 0.98	Total Stockholder Equity